Sharon Hesterlee's Blog – October 2012 Archive (2)
Better, Faster, Now!
These are the words that best describe PPMD’s research plan.
- We aim to put better drugs into development for clinical trials because we can’t afford the failures.
- We apply funding strategically to increase the speed of testing new drugs.
- We prioritize and fund the testing in Duchenne of drugs that are already approved for other purposes.
Everything we do goes through this filter to make sure that we are achieving one of these…
ContinueAdded by Sharon Hesterlee on October 11, 2012 at 11:00am — 4 Comments
Positive Phase 1 trial results for SMT C1100 in Duchenne (Summit PLC)
Following closely on the heels of the good news about Sarepta’s exon 51 skipping strategy, PPMD is pleased to report that Summit…
Added by Sharon Hesterlee on October 10, 2012 at 10:30am — 13 Comments
Latest Blog Posts
Most Popular Blog Posts
- GSK and Prosensa announce primary endpoint not met in Phase III study of drisapersen
- Positive Phase 1 trial results for SMT C1100 in Duchenne (Summit PLC)
- Now is the time for strength.
- Without Endings There Are No Beginnings…
- Parent Project Muscular Dystrophy awards $50,000 to Dr. Toshifumi Yokota for multi-exon skipping project
- Drug Development Prospects for Duchenne: The Pipeline is rich and deep, with lots of forward momentum
- World Muscle Society Congress: Next Generation Exon-Skipping & Clinical Trial Updates
© 2021 Created by PPMD.
Powered by
Badges | Report an Issue | Privacy Policy | Terms of Service
